Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Imugene Limited (IMU.AX)
Sydney, NSW, AU
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
4 articles
- Figma shares rise as Bank of America resumes coverage with a ‘Buy’ rating Proactive Investors - Finance
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -14.81% | +0.00% | -52.08% | -66.67% | -68.49% | -77.45% | -96.78% | -99.15% | -65.87% | -99.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-11.5% Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+55.6% ★ Q4'25: +61.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,486.9%
-
EBIT margin Biotechnology: +0.0%-1,593.5%
-
ROIC Biotechnology: -16.1%-207.6% Q4'25: -493.7% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+4.9% Q4'25: +44.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q4'25: -0.03× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 2 EPS Ana. |
Jun 2027 1 Rev. Ana. 2 EPS Ana. |
Jun 2028 1 Rev. Ana. 2 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
638.7K
est: 343.0K (+86.2%)
|
1.56M
est: 800.0K (+95.5%)
|
1.16M
est: 840.0K (+38.6%)
|
1.84M
est: 1.63M (+12.9%)
|
4.13M
est: 2.40M (+72.0%)
|
4.13M
est: 3.40M (+21.6%)
|
7.23M
est: 7.39M (-2.2%)
|
11.78M
est: 9.00M (+30.9%)
|
4.97M
est: 8.00M (-37.9%)
|
4.40M
est: 14.00M (-68.6%)
|
2.50M
470.7K – 4.53M
-82.1% YoY
|
2.50M
1.04M – 3.96M
+0.0% YoY
|
16.80M
6.97M – 26.63M
+572.0% YoY
|
967.96M
401.55M – 1.53B
+5,661.7% YoY
|
| EBITDA |
-195.0K
est: -343.0K (+43.1%)
|
-4.25M
est: -6.30M (+32.6%)
|
-3.67M
est: -840.0K (-336.8%)
|
-5.77M
est: -12.84M (+55.0%)
|
-7.71M
est: -5.92M (-30.1%)
|
-14.55M
est: -13.65M (-6.6%)
|
-23.72M
est: -17.92M (-32.4%)
|
-47.43M
est: -9.00M (-426.9%)
|
-147.98M
est: -8.00M (-1,749.7%)
|
-67.42M
est: -14.00M (-381.6%)
|
-2.50M
-4.53M – -470.7K
+82.1% YoY
|
-2.50M
-3.96M – -1.04M
+0.0% YoY
|
-16.80M
-26.63M – -6.97M
-572.0% YoY
|
-967.96M
-1.53B – -401.55M
-5,661.7% YoY
|
| EBIT |
-3.04M
est: -343.0K (-786.6%)
|
-4.25M
est: -6.72M (+36.8%)
|
-3.67M
est: -840.0K (-337.0%)
|
-5.77M
est: -13.70M (+57.9%)
|
-8.26M
est: -5.65M (-46.1%)
|
-14.64M
est: -13.65M (-7.3%)
|
-25.68M
est: -18.96M (-35.4%)
|
-49.63M
est: -9.00M (-451.4%)
|
-153.82M
est: -8.00M (-1,822.7%)
|
-70.06M
est: -14.00M (-400.5%)
|
-2.50M
-4.53M – -470.7K
+82.1% YoY
|
-2.50M
-3.96M – -1.04M
+0.0% YoY
|
-16.80M
-26.63M – -6.97M
-572.0% YoY
|
-967.96M
-1.53B – -401.55M
-5,661.7% YoY
|
| Net Income |
-2.44M
est: -455.1K (-436.3%)
|
-2.73M
est: -6.51M (+58.0%)
|
-2.51M
est: -10.32M (+75.7%)
|
-3.93M
est: -13.27M (+70.4%)
|
-7.78M
est: -5.79M (-34.3%)
|
-10.51M
est: -13.65M (+23.0%)
|
-18.46M
est: -18.44M (-0.1%)
|
-37.92M
est: -37.91M (0.0%)
|
-149.68M
est: -54.97M (-172.3%)
|
-69.02M
est: -69.02M (+0.0%)
|
-20.95M
-31.49M – -10.41M
+69.6% YoY
|
-16.01M
-19.03M – -12.99M
+23.6% YoY
|
-9.66M
-12.31M – -7.00M
+39.7% YoY
|
371.80M
88.97M – 654.70M
+3,950.5% YoY
|
| SGA |
1.22M
est: 1.52M (-20.2%)
|
1.57M
est: 3.55M (-55.8%)
|
1.21M
est: 3.73M (-67.5%)
|
1.21M
est: 7.24M (-83.3%)
|
4.78M
est: 2.40M (+99.2%)
|
5.52M
est: 15.10M (-63.5%)
|
9.59M
est: 32.83M (-70.8%)
|
18.23M
est: 39.96M (-54.4%)
|
59.91M
est: 35.52M (+68.6%)
|
27.77M
est: 62.17M (-55.3%)
|
11.10M
2.09M – 20.11M
-82.1% YoY
|
11.10M
4.61M – 17.60M
+0.0% YoY
|
74.60M
30.95M – 118.26M
+572.0% YoY
|
4.30B
1.78B – 6.81B
+5,661.7% YoY
|
| EPS |
-0.07
est: 0.00 (-3,302.2%)
|
-0.07
est: -0.05 (-38.1%)
|
-0.04
est: -0.05 (+14.4%)
|
-0.05
est: -0.06 (+11.8%)
|
-0.07
est: -0.06 (-14.2%)
|
-0.09
est: -0.10 (+14.0%)
|
-0.13
est: -0.10 (-36.6%)
|
-0.21
est: -0.29 (+28.7%)
|
-0.72
est: -0.25 (-186.4%)
|
-0.32
est: -0.68 (+52.9%)
|
-0.10
-0.14 – -0.05
+85.9% YoY
|
-0.07
-0.09 – -0.06
+23.6% YoY
|
-0.04
-0.06 – -0.03
+39.7% YoY
|
1.70
0.41 – 2.99
+3,950.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Leslie Chong | Chief Executive Officer, MD & Executive Director | 1M | female |
| John Byon | Chief Medical Officer | 787.7K | — |
| Darren Michael Keamy | Chief Financial Officer & Company Secretary | 408.9K | male |
| Paul Edward-Alexander Hopper FAICD | Executive Chairman | 330.7K | male |
| Ursula McCurry | Chief Clinical Operations Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMU.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
